Orchestra BioMed Holdings, Inc. reported a net loss of $18.755 million for the three months ended March 31, 2025, an increase from the $13.463 million net loss in the same period last year. Total revenue for the quarter was $0.868 million, primarily driven by partnership and product revenues. The company continues to incur substantial operating losses and anticipates needing additional capital to fund its operations.

Orchestra BioMed Holdings, Inc. reported a net loss of $61.0 million for the year ended December 31, 2024, an increase from the $49.1 million net loss in the previous year. Total revenue for the year was $2.638 million, a slight decrease from $2.760 million in 2023. The company continues to incur substantial expenses, particularly in research and development, and anticipates needing additional funding to support its operations and product commercialization goals.